PharmaCyte Biotech, Inc. PMCB
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -57.14%
- 1 year
- -66.63%
- Open
- 0.31
- Prev close
- 0.3021
- Mkt cap
- 3.33M
- Vol
- 40.84K
- Avg vol
- 183.73K
- EPS
- -2.31
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.31
- High
- 0.32
- Forward P/E
- -4.21
- Beta
- -0.20
- Short ratio
- 1.09
- Inst. own
- 13.16%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.73
- 200-d avg
- 1.94
- 1y target
- 0.00
News
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Onconetix (NASDAQ:ONCO) stock increased by 10.3% to $1.14 during Friday's after-market session. The market value of their outstanding shares is at $3.9 million. Bullfrog AI Hldgs…
-
1 month ago benzinga.com
PharmaCyte Biotech Q1 EPS $(0.54) Up From $(1.23) YoY, Sales $0.00, Same YoY
PharmaCyte Biotech (NASDAQ:PMCB) reported quarterly losses of $(0.54) per share. This is a 56.1 percent increase over losses of $(1.23) per share from the same period last year. The company reported…
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
11 months ago benzinga.com
PharmaCyte Biotech Receives Noncompliance Notice From Nasdaq; Has Until June 2026 To Regain Compliance
On December 1, 2025, PharmaCyte Biotech, Inc. (the "Company") received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating…
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
11 months ago benzinga.com
Why Autodesk Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Why Autodesk Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
11 months ago benzinga.com
PharmaCyte Biotech Monetizes Femasys Stake; Cash And Securities Expected At ~$20M After Monetization, Up From $13.3M
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ:FEMY), further validating the Company's…
-
1 year ago benzinga.com
PharmaCyte Biotech Q1 EPS $(1.23) Down From $1.90 YoY
PharmaCyte Biotech (NASDAQ:PMCB) reported quarterly losses of $(1.23) per share. This is a 164.74 percent decrease over earnings of $1.90 per share from the same period last year.
-
1 year ago benzinga.com
PharmaCyte Biotech Invests Additional $3M In TNF Pharmaceuticals To Support LightSolver Partnership
TNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner's 2025 Hype Cycle for Data Center Infrastructure TechnologiesPharmaCyte Biotech,…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
PharmaCyte Biotech Q4 EPS $1.54 Up From $(0.33) YoY
PharmaCyte Biotech (NASDAQ:PMCB) reported quarterly earnings of $1.54 per share. This is a 566.67 percent increase over losses of $(0.33) per share from the same period last year.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
2 years ago benzinga.com
PharmaCyte Biotech Makes $7M Investment In MyMD Pharmaceuticals; Investment In Life Sciences Solidifies Previously Announced Strategy To Utilize Significant Cash Position To Create Additional Stockholder Value
Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder valuePharmaCyte Biotech, Inc. (NASDAQ:PMCB)…
-
2 years ago benzinga.com
PharmaCyte Biotech Acquires $5M Stake In Emerging Women's Health Innovator Femasys, Inc.
New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder valuePharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company")…
-
3 years ago benzinga.com
PharmaCyte Biotech Provides Corporate Update On Cell-In-A-Box Technology
Company prepares for comprehensive discussion with FDA to determine appropriate next steps for technology while evaluating additional opportunitiesPharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte"…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 369 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 386 stocks made new 52-week lows.
-
3 years ago benzinga.com
Pancreatic Cancer Action Network Urges Advocates From All 50 States To Call On Congress To Increase Federal Funding For Pancreatic Cancer Research
Federal Funding Increases Fuel Research Progress and Help Improve Patient OutcomesLOS ANGELES, June 14, 2023 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer…
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
3 years ago benzinga.com
PharmaCyte Biotech Announces Cash Tender Offer For Up To 7.75M Shares At $3.25 Per Share
Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 per Share PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the
-
4 years ago benzinga.com
PharmaCyte Biotech Board Of Directors Announces Business Review Committee To Evaluate Opportunities To Optimize Shareholder Value; CEO Kenneth L. Waggoner Has Stepped Down From The Position As CEO Effective October 6, Joshua N. Silverman As Interim CEO
LAS VEGAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), a biotechnology company focused on evaluating its signature live-cell encapsulation
-
4 years ago benzinga.com
PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation
https://pharmacyte.com/pharmacyte-biotech-rebukes-iroquois-commencement-of-consent-solicitation/
-
4 years ago benzinga.com
PharmaCyte Biotech Reports Interim Results in Malignant Ascites Mouse Model Study
PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation…
-
4 years ago benzinga.com
PharmaCyte Biotech Announces Additional Quality Control Assay And Confirms Stability Of CypCap Cells
PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation…
-
4 years ago benzinga.com
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell…
-
4 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
-
5 years ago benzinga.com
78 Biggest Movers From Friday
Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Thursday
Stocks That Hit 52-Week Highs On Thursday